GleamWall
中文EN

DMAC DiaMedica Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-26.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.2%
ROA-86.3%
ROIC (approx.)-94.2%
Asset turnover—

Leverage & solvency

Liabilities / assets20.7%
Debt / equity0.00x
Current ratio4.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$9.24M$8.15M$7.99M$6.70M$6.44M$5.82M$5.66M$6.47M
SG&A expense$2.38M$2.35M$2.50M$2.51M$2.60M$2.19M$2.49M$1.95M
Operating income-$11.62M-$10.50M-$10.48M-$9.21M-$9.03M-$8.01M-$8.14M-$8.42M
Pretax income-$11.30M-$10.13M-$10.04M-$8.73M-$8.61M-$7.69M-$7.70M-$7.89M
Income tax$8,000$7,000$7,000$10,000$6,000$6,000$6,000$9,000
Net income-$11.31M-$10.14M-$10.04M-$8.74M-$8.62M-$7.70M-$7.71M-$7.90M
EBITDA-$11.61M-$10.49M-$10.47M-$9.20M-$9.02M-$8.00M-$8.13M-$8.41M
EPS (basic)-0.21-0.19-0.19—-0.17-0.18-0.18—
EPS (diluted)————————
Balance sheet
Cash & equivalents$6.80M$5.13M$4.87M$15.65M$3.33M$4.11M$2.59M$3.02M
Short-term investments$28.11M$38.38M$46.46M$44.24M$51.99M$25.93M$33.73M$41.12M
Receivables$176,000$244,000$301,000$258,000$260,000$161,000$253,000$236,000
Current assets$35.49M$44.31M$52.36M$60.63M$56.22M$31.08M$37.42M$44.61M
PP&E, net$131,000$133,000$142,000$145,000$150,000$152,000$149,000$148,000
Total assets$36.15M$45.00M$53.08M$61.37M$57.05M$31.47M$38.83M$46.34M
Current liabilities$7.45M$6.59M$5.75M$5.13M$5.27M$4.12M$4.67M$5.39M
Total liabilities$7.49M$6.66M$5.84M$5.26M$5.42M$4.30M$4.88M$5.63M
Shareholders' equity$28.66M$38.34M$47.23M$56.11M$51.62M$27.17M$33.95M$40.72M
Shares outstanding53.96M53.93M53.88M53.74M52.08M43.07M42.86M42.82M
Cash flow statement
Operating cash flow-$8.83M-$8.11M-$9.08M-$7.76M-$6.55M-$7.60M-$7.15M-$6.43M
Capital expenditure$10,000$3,000$8,000$6,000$16,000$6,000$12,000$7,000
Free cash flow-$8.84M-$8.12M-$9.09M-$7.77M-$6.57M-$7.60M-$7.16M-$6.44M
Investing cash flow$10.39M$8.24M-$2.11M$8.00M-$25.77M$8.96M$6.62M$5.21M
Financing cash flow$114,000$132,000$417,000$12.09M$31.53M$161,000$91,000$120,000
Depreciation & amortization$12,000$12,000$11,000$11,000$18,000$3,000$11,000$11,000
Stock-based compensation$1.53M$1.12M$822,000$1.19M$1.02M$771,000$867,000$589,000

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.